TabletsClinical Overview
Cefpodoxime Proxetil and Ofloxacin is a broad-spectrum combination of an oral 3rd-generation cephalosporin prodrug and a second-generation fluoroquinolone. Cefpodoxime blocks cell wall synthesis while ofloxacin halts DNA replication and transcription via bacterial DNA gyrase and topoisomerase IV inhibition. Indicated for mixed and resistant respiratory tract infections, enteric fever, and complicated skin or urinary infections.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Swallow whole with water, preferably with meals (food substantially enhances cefpodoxime absorption). Drink plenty of fluids during treatment. Avoid taking within 2 hours of antacids or mineral supplements. Complete the full course.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, diarrhea, abdominal cramps, headache, dizziness, insomnia. Rare/Severe: Fluoroquinolone-induced tendon rupture, QT prolongation, peripheral neuropathy, and Clostridioides difficile colitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Boxed warning for fluoroquinolone tendon and neurologic risks. Contraindicated in myasthenia gravis, history of fluoroquinolone tendonitis, or cephalosporin allergy. Not recommended in pediatric age groups or pregnancy.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Cefpodoxime Proxetil Dispersible Tablets 100 mg
Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.
Cefpodoxime Tablets 200 mg
Cefpodoxime Proxetil is an orally absorbed prodrug of the third-generation cephalosporin cefpodoxime. Following absorption, it is de-esterified into active cefpodoxime, which inhibits bacterial cell wall synthesis. Active against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Proteus mirabilis. Indicated for community-acquired pneumonia, acute otitis media, pharyngitis, sinusitis, uncomplicated skin infections, and uncomplicated UTIs.
Ofloxacin 200mg + Ornidazole 500mg Tablets
Ofloxacin and Ornidazole is a broad-spectrum fixed-dose antimicrobial combination pairing a fluoroquinolone with a nitroimidazole. Ofloxacin halts bacterial DNA multiplication, while ornidazole damages microbial DNA through free nitro radicals, eradicating anaerobes and protozoa. Indicated for mixed bacterial and protozoal gastroenteritis, amoebic dysentery, pelvic inflammatory disease, dental infections, and post-surgical abdominal sepsis.
Ofloxacin Tablets 200mg
Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.